Bli medlem
Bli medlem

Du är här

2015-12-03

Solvay S.A.: Solvay launches a € 1.5 billion rights issue in the context of the intended Cytec acquisition

Solvay S.A.: Solvay launches a € 1.5 billion rights issue in the context of the intended Cytec acquisition

Ratio: 1 new share for 4 rights

Subscription price: € 70.83 per new share
Subscription period: December 4, 2015 to December 15, 2015 included

Brussels, December 3, 2015, 07:00 ---
Solvay announces today the launch of a rights issue of € 1.5 billion to
complete the financing of the intended acquisition of U.S.-based Cytec, which
is expected to close on December 9, 2015. The acquisition will significantly
boost Solvay's portfolio of advanced materials with lightweighting solutions
for the aerospace and automotive industries, and will furthermore strengthen
its formulations know-how in mining chemicals. With Cytec, Solvay will
accelerate its transformation to achieve higher growth, returns and
resilience.

The rights issue entails an offering of 21,175,283 new shares at a
subscription price of € 70.83 per new share, with preference rights for
existing shareholders at a ratio of 1 new share for 4 rights, each existing
shareholder being granted one right per existing share held. Solvay's
reference shareholder Solvac has committed to fully exercise its rights and
subscribe for the resulting number of new shares, thereby maintaining its
current 30.20% stake in the share capital of Solvay.

The main terms of the offering can be summarised as follows:

Rights:
Subject to applicable securities laws, all Solvay shareholders as of the
closing of Euronext Brussels and Euronext Paris on December 3, 2015, are
being granted one right per existing share held. The rights, represented by
coupon n° 97 of the existing shares, will be separated from such shares on
December 3, 2015, after the closing of Euronext Brussels and Euronext Paris.

Ratio:
1 new share for 4 rights (the "Ratio").

Subscription price:
€ 70.83 per new share.

Rights subscription period:
From December 4, 2015, to 4.00pm CET on December 15, 2015, inclusive. Rights
that have not been exercised by the end of the rights subscription period
will no longer be exercisable.

Scrips subscription period:
After the rights subscription period has expired, any rights that have not
been exercised will be converted into an equal number of scrips. Except if in
the reasonable opinion of the banks underwriters it is unlikely that any
subscribers can be procured, the scrips will be offered and sold through an
accelerated bookbuilding process in an exempt private placement. Such
placement is expected to take place on or around December 16 or 17, 2015, but
may be extended

The net proceeds of the scrips (if any) will accrue to the holders of the
rights that have not been exercised during the rights subscription period,
unless the net proceeds of the sale of the scrips divided by the number of
unexercised rights is less than € 0.01 in which case such net proceeds will
be transferred to Solvay. Purchasers of scrips will have the obligation to
subscribe for new shares corresponding to the scrips acquired by them in
accordance with the Ratio.

Announcement of the results:
The results of the offering are expected to be announced on or around December
17, 2015.

Ranking and dividends:
The new shares shall have the same rights and benefits as, and shall rank pari
passu in all respects, including as to entitlement to dividends, with, the
existing shares and will be entitled to distributions in respect of which the
relevant record date or due date falls on or after their issue date.

Settlement:
The payment of the subscriptions with rights is expected to take place on or
around December 21, 2015. The payment of the subscriptions with scrips is
expected to take place on or around December 21, 2015. Delivery of the new
shares and payment of any net proceeds of the scrips will take place on or
around December 21, 2015.

Additional information, subject to applicable legal restrictions, is available
at:http://www.solvay.com/en/investors/cytec-acquisition-financing/index.html.

* * * * *

These written materials do not constitute an offer to sell, or a solicitation
of offers to purchase or subscribe for, securities in the United States or
any other jurisdiction. The securities referred to herein have not been, and
will not be, registered under the Securities Act of 1933, as amended, and may
not be offered, exercised or sold in the United States absent registration or
an applicable exemption from registration requirements. There is no intention
to register any portion of the offering in the United States or to conduct a
public offering of securities in the United States.

The issue, exercise or sale of securities in the offering are subject to
specific legal or regulatory restrictions in certain jurisdictions. Solvay
assumes no responsibility in the event there is a violation by any person of
such restrictions.

The information contained herein shall not constitute or form part of an offer
to sell or the solicitation of an offer to buy, nor shall there be any sale
of the securities referred to herein, in any jurisdiction in which such
offer, solicitation or sale would be unlawful. The distribution of this press
release may be restricted by law or regulation in certain countries.
Accordingly, persons who come into possession of this press release should
inform themselves of and observe such restrictions.

Solvay has not authorized any offer to the public of securities in any Member
State of the European Economic Area other than Belgium and France. With
respect to each Member State of the European Economic Area other than Belgium
and France and which has implemented the Prospectus Directive (each, a
"Relevant Member State"), no action has been undertaken or will be undertaken
to make an offer to the public of securities requiring publication of a
prospectus in any Relevant Member State. As a result, the securities may only
be offered in Relevant Member States (a) to any legal entity which is a
qualified investor as defined in Article 2(1)(e) of the Prospectus Directive;
or (b) in any other circumstances which do not require the publication by
Solvay of a prospectus pursuant to Article 3 of the Prospectus Directive. For
the purposes of this paragraph, the expression an "offer of securities to the
public" means the communication in any form and by any means of sufficient
information on the terms of the offer and the securities to be offered so as
to enable an investor to decide to exercise, purchase or subscribe the
securities, as the same may be varied in that Member State by any measure
implementing the Prospectus Directive in that Member State and the expression
"Prospectus Directive" means Directive 2003/71/EC (and amendments thereto,
including the 2010 PD Amending Directive, to the extent implemented in the
Relevant Member State), and includes any relevant implementing measure in the
Relevant Member State and the expression "2010 PD Amending Directive" means
Directive 2010/73/EU.

This communication is directed only at (i) persons who are outside the United
Kingdom or (ii) in the United Kingdom, persons who have professional
experience in matters relating to investments falling within Article 19(5) of
the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005,
as amended (the "Order"), or who are high net worth entities, and other
persons to whom it may lawfully be communicated, falling within Article 49(2)
of the Order (all such persons together being referred to as "relevant
persons"). Any investment or investment activity to which this communication
relates will only be available to and will only be engaged in with, relevant
persons. Any person who is not a relevant person must not act or rely on this
document or any of its contents.

Follow us on twitter @SolvayGroup

--------------------------------------------------------------------------------
| As an international chemical group,Solvayassists industries in finding and |
|implementing ever more responsible and value-creating solutions. Solvay |
|generates 90% of its net sales in activities where it is among the world's |
|top three players. It serves many markets, varying from energy and the |
|environment to automotive and aerospace or electricity and electronics, with |
|one goal: to raise the performance of its clients and improve society's |
|quality of life. The group is headquartered in Brussels, employs about 26,000 |
|people in 52 countries and generated 10.2 billion euros in net sales in 2014. |
|Solvay SA (SOLB.BE) is listed onEuronextin Brussels and Paris (Bloomberg: |
|SOLB.BB - Reuters:SOLB.BR). |
--------------------------------------------------------------------------------

-------------------------------------------------------------------------------------------------
| Lamia Narcisse Caroline Jacobs Maria Alcon Geoffroy Raskin Bisser Alexandrov |
| Media Relations Media Relations Investor Relations Investor Relations Investor Relations |
|+33 1 53 56 59 62 +32 2 264 1530 +32 2 264 1984 +32 2 264 1540 +32 2 264 3687 |
-------------------------------------------------------------------------------------------------

To read this release in PDF
http://hugin.info/133981/R/1970070/720728.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Solvay S.A. via Globenewswire

HUG#1970070

Författare SIX news

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.